A detailed history of Rhumbline Advisers transactions in Abb Vie Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 3,086,273 shares of ABBV stock, worth $556 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares
3,086,273
Previous 3,162,161 2.4%
Holding current value
$556 Million
Previous $542 Million 12.37%
% of portfolio
0.56%
Previous 0.52%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$163.84 - $199.33 $12.4 Million - $15.1 Million
-75,888 Reduced 2.4%
3,086,273 $609 Million
Q2 2024

Aug 01, 2024

SELL
$154.79 - $180.76 $14.4 Million - $16.9 Million
-93,350 Reduced 2.87%
3,162,161 $542 Million
Q1 2024

May 09, 2024

SELL
$159.82 - $182.1 $4.36 Million - $4.97 Million
-27,308 Reduced 0.83%
3,255,511 $593 Million
Q4 2023

Feb 08, 2024

BUY
$137.6 - $154.97 $2.27 Million - $2.55 Million
16,469 Added 0.5%
3,282,819 $509 Million
Q3 2023

Nov 09, 2023

BUY
$133.59 - $154.65 $3.11 Million - $3.6 Million
23,250 Added 0.72%
3,266,350 $487 Million
Q2 2023

Aug 08, 2023

BUY
$132.51 - $164.9 $9.73 Million - $12.1 Million
73,451 Added 2.32%
3,243,100 $437 Million
Q1 2023

May 11, 2023

BUY
$144.61 - $166.54 $24.6 Million - $28.3 Million
170,080 Added 5.67%
3,169,649 $505 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $16.1 Million - $19.3 Million
116,421 Added 4.04%
2,999,569 $485 Million
Q3 2022

Nov 10, 2022

BUY
$134.21 - $153.93 $13.2 Million - $15.1 Million
98,281 Added 3.53%
2,883,148 $387 Million
Q2 2022

Aug 11, 2022

BUY
$137.62 - $174.96 $13.9 Million - $17.6 Million
100,697 Added 3.75%
2,784,867 $427 Million
Q1 2022

May 12, 2022

BUY
$131.98 - $163.75 $2.16 Million - $2.68 Million
16,348 Added 0.61%
2,684,170 $435 Million
Q4 2021

Feb 10, 2022

BUY
$107.43 - $135.93 $4.05 Million - $5.12 Million
37,662 Added 1.43%
2,667,822 $361 Million
Q3 2021

Nov 12, 2021

SELL
$106.4 - $120.78 $5.46 Million - $6.2 Million
-51,334 Reduced 1.91%
2,630,160 $284 Million
Q2 2021

Aug 05, 2021

SELL
$105.21 - $117.21 $16 Million - $17.8 Million
-151,918 Reduced 5.36%
2,681,494 $302 Million
Q1 2021

May 06, 2021

SELL
$102.3 - $112.62 $16.4 Million - $18.1 Million
-160,379 Reduced 5.36%
2,833,412 $307 Million
Q4 2020

Feb 10, 2021

SELL
$80.49 - $108.67 $4.31 Million - $5.82 Million
-53,584 Reduced 1.76%
2,993,791 $321 Million
Q3 2020

Nov 12, 2020

BUY
$85.91 - $100.83 $2.33 Million - $2.73 Million
27,064 Added 0.9%
3,047,375 $267 Million
Q2 2020

Aug 13, 2020

BUY
$73.37 - $98.18 $51.4 Million - $68.8 Million
700,976 Added 30.22%
3,020,311 $297 Million
Q1 2020

May 06, 2020

BUY
$64.5 - $97.79 $299,086 - $453,452
4,637 Added 0.2%
2,319,335 $177 Million
Q4 2019

Feb 05, 2020

SELL
$72.13 - $90.25 $2.13 Million - $2.67 Million
-29,539 Reduced 1.26%
2,314,698 $205 Million
Q3 2019

Oct 23, 2019

BUY
$62.98 - $75.72 $1.49 Million - $1.79 Million
23,679 Added 1.02%
2,344,237 $178 Million
Q2 2019

Aug 14, 2019

SELL
$65.7 - $83.98 $4.81 Million - $6.15 Million
-73,248 Reduced 3.06%
2,320,558 $169 Million
Q1 2019

May 01, 2019

BUY
$77.14 - $90.79 $6.36 Million - $7.49 Million
82,463 Added 3.57%
2,393,806 $193 Million
Q4 2018

Jan 31, 2019

SELL
$77.85 - $96.01 $710,848 - $876,667
-9,131 Reduced 0.39%
2,311,343 $213 Million
Q3 2018

Nov 07, 2018

SELL
$88.91 - $98.84 $8.23 Million - $9.15 Million
-92,562 Reduced 3.84%
2,320,474 $219 Million
Q2 2018

Aug 06, 2018

SELL
$89.78 - $106.23 $3.17 Million - $3.76 Million
-35,356 Reduced 1.44%
2,413,036 $224 Million
Q1 2018

May 02, 2018

SELL
$92.01 - $123.21 $5.04 Million - $6.75 Million
-54,752 Reduced 2.19%
2,448,392 $232 Million
Q4 2017

Feb 09, 2018

BUY
$89.56 - $98.21 $5.24 Million - $5.75 Million
58,509 Added 2.39%
2,503,144 $242 Million
Q3 2017

Nov 06, 2017

BUY
$69.85 - $89.22 $171 Million - $218 Million
2,444,635
2,444,635 $217 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.